So, there is a new study which shows that mercury-based vaccines can cause brain changes found in autism. It supports the data found in the following compelling charts which juxtapose mercury toxicity symptoms versus the symptoms of autism:
Autism: a Novel Form of Mercury Poisoning
Autism Research Institute
Table I: Summary Comparison of Traits of Autism & Mercury Poisoning (Autism Spectrum Disorder (ASD) references in bold; Mercury poisoning (HgP) references in italics)
|Social deficits, shyness, social withdrawal (1,2,130,131; 21,31,45,53,132)|
|Repetitive, perseverative, stereotypic behaviors; obsessive-compulsive tendencies (1,2,43,48,133; 20,33-35,132)|
|Depression/depressive traits, mood swings, flat affect; impaired face recognition (14,15,17,103, 134,135; 19,21,24,26,31)|
|Anxiety; schizoid tendencies; irrational fears (2,15,16; 21,27,29,31)|
|Irritability, aggression, temper tantrums (12,13,43; 18,21,22,25)|
|Lacks eye contact; impaired visual fixation (HgP)/ problems in joint attention (ASD) (3,36,136,137; 18,19,34)|
|Speech and Language Deficits|
|Loss of speech, delayed language, failure to develop speech (1-3,138,139; 11,23,24,27,30,37)|
|Dysarthria; articulation problems (3; 21,25,27,39)|
|Speech comprehension deficits (3,4,140; 9,25,34,38)|
|Verbalizing and word retrieval problems (HgP); echolalia, word use and pragmatic errors (ASD) (1,3,36; 21,27,70)|
|Abnormal sensation in mouth and extremities (2,49; 25,28,34,39)|
|Sound sensitivity; mild to profound hearing loss (2,47,48; 19,23-25,39,40)|
|Abnormal touch sensations; touch aversion (2,49; 23,24,45,53)|
|Over-sensitivity to light; blurred vision (2,50,51; 18,23,31,34,45)|
|Flapping, myoclonal jerks, choreiform movements, circling, rocking, toe walking, unusual postures (2,3,43,44; 11,19,27,30,31,34,39)|
|Deficits in eye-hand coordination; limb apraxia; intention tremors (HgP)/problems with intentional movement or imitation (ASD) (2,3,36,181; 25,29,32,38,70,87)|
|Abnormal gait and posture, clumsiness and incoordination; difficulties sitting, lying, crawling, and walking; problem on one side of body (4,41,42,123; 18,25,31,34,39,45)|
|Borderline intelligence, mental retardation – some cases reversible (2,3,151,152; 19,25,31,39,70)|
|Poor concentration, attention, response inhibition (HgP)/shifting attention (ASD) (4,36,153; 21,25,31,38,141)|
|Uneven performance on IQ subtests; verbal IQ higher than performance IQ (3,4,36; 31,38)|
|Poor short term, verbal, and auditory memory (36,140; 21,29,31,35,38,87,141)|
|Poor visual and perceptual motor skills; impairment in simple reaction time (HgP)/ lower performance on timed tests (ASD) (4,140,181; 21,29,142)|
|Deficits in understanding abstract ideas & symbolism; degeneration of higher mental powers (HgP)/sequencing, planning & organizing (ASD); difficulty carrying out complex commands (3,4,36,153; 9,18,37,57,142)|
|Self injurious behavior, e.g. head banging (3,154; 11,18,53)|
|ADHD traits (2,36,155; 35,70)|
|Agitation, unprovoked crying, grimacing, staring spells 3,154; 11,23,37,88)|
|Sleep difficulties (2,156,157; 11,22,31)|
|Hyper- or hypotonia; abnormal reflexes; decreased muscle strength, especially upper body; incontinence; problems chewing, swallowing (3,42,145,181; 19,27,31,32,39)|
|Rashes, dermatitis, eczema, itching (107,146; 22,26,143)|
|Diarrhea; abdominal pain/discomfort, constipation, “colitis” (107,147-149; 18,23,26,27,31,32)|
|Anorexia; nausea (HgP)/vomiting (ASD); poor appetite (HgP)/restricted diet (ASD) (2,123; 18,22)|
|Lesions of ileum and colon; increased gut permeability (147,150; 57,144)|
Table II: Summary Comparison of Biological Abnormalities in Autism & Mercury Exposure
|Binds -SH groups; blocks sulfate transporter in intestines, kidneys (40,93)||Low sulfate levels (91,92)|
|Reduces glutathione availability; inhibits enzymes of glutathione metabolism; glutathione needed in neurons, cells, and liver to detoxify heavy metals; reduces glutathione peroxidase and reductase (97,100,161,162)||Low levels of glutathione; decreased ability of liver to detoxify xenobiotics; abnormal glutathione peroxidase activity in erythrocytes (91,94,95)|
|Disrupts purine and pyrimidine metabolism (10,97,158,159)||Purine and pyrimidine metabolism errors lead to autistic features (2,101,102)|
|Disrupts mitochondrial activities, especially in brain (160,163,164)||Mitochondrial dysfunction, especially in brain (76,172)|
|Sensitive individuals more likely to have allergies, asthma, autoimmune-like symptoms, especially rheumatoid-like ones (8,11,18,24,28,31,111,113)||More likely to have allergies and asthma; familial presence of autoimmune diseases, especially rheumatoid arthritis; IgA deficiencies (103,106-109,115)|
|Can produce an immune response in CNS; causes brain/MBP autoantibodies (18,111,165)||On-going immune response in CNS; brain/MBP autoantibodies present (104,105,109,110)|
|Causes overproduction of Th2 subset; kills/inhibits lymphocytes, T-cells, and monocytes; decreases NK T-cell activity; induces or suppresses IFNg & IL-2 (100,112,117-120,166)||Skewed immune-cell subset in the Th2 direction; decreased responses to T-cell mitogens; reduced NK T-cell function; increased IFNg & IL-12 (103,108,114-116,173,174)|
|Selectively targets brain areas unable to detoxify or reduce Hg-induced oxidative stress (40,56,161)||Specific areas of brain pathology; many functions spared (36)|
|Accummulates in amygdala, hippocampus, basal ganglia, cerebral cortex; damages Purkinje and granule cells in cerebellum; brain stem defects in some cases (10,34,40,70-73)||Pathology in amygdala, hippocampus, basal ganglia, cerebral cortex; damage to Purkinje and granule cells in cerebellum; brain stem defects in some cases (36,60-69)|
|Causes abnormal neuronal cytoarchitecture; disrupts neuronal migration, microtubules, and cell division; reduces NCAMs (10,28,57-59,161)||Neuronal disorganization; increased neuronal cell replication, increased glial cells; depressed expression of NCAMs (4,54,55)|
|Progressive microcephaly (24)||Progressive microcephaly and macrocephaly (175)|
|Prevents presynaptic serotonin release and inhibits serotonin transport; causes calcium disruptions (78,79,163,167,168)||Decreased serotonin synthesis in children; abnormal calcium metabolism (76,77,103,179)|
|Alters dopamine systems; peroxidine deficiency in rats resembles mercurialism in humans (8,80)||Either high or low dopamine levels; positive response to peroxidine, which lowers dopamine levels (2,177,178)|
|Elevates epinephrine and norepinephrine levels by blocking enzyme that degrades epinephrine (81,160)||Elevated norepinephrine and epinephrine (2)|
|Elevates glutamate (21,171)||Elevated glutamate and aspartate (82,176)|
|Leads to cortical acetylcholine deficiency; increases muscarinic receptor density in hippocampus and cerebellum (57,170)||Cortical acetylcholine deficiency; reduced muscarinic receptor binding in hippocampus (83)|
|Causes demyelinating neuropathy (22,169)||Demyelination in brain (105)|
|Causes abnormal EEGs, epileptiform activity, variable patterns, e.g., subtle, low amplitude seizure activities (27,31,34,86-89)||Abnormal EEGs, epileptiform activity, variable patterns, including subtle, low amplitude seizure activities (2,4,84,85)|
|Causes abnormal vestibular nystagmus responses; loss of sense of position in space (9,19,34,70)||Abnormal vestibular nystagmus responses; loss of sense of position in space (27,180)|
|Results in autonomic disturbance: excessive sweating, poor circulation, elevated heart rate (11,18,31,45)||Autonomic disturbance: unusual sweating, poor circulation, elevated heart rate (17,180)|
1 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington D.C.: American Psychiatric Association, 1994.
2 Gillberg C., Coleman M. The Biology of the Autistic Syndromes, 2nd edn. London: Mac Keith Press, 1992.
3 Filipek P., Accardo P., Baranek G., et al. The screening and diagnosis of autistic spectrum disorders. J Autism Dev Disord 1999; 29(6): 439-484.
4 Bailey A., Phillips W., Rutter M. Autism: towards an integration of clinical, genetic, neuro-psychological, and neurobiological perspectives. J Child Psychol Psychiatry 1996; 37(1): 89-126.
5 Suzuki T., Takemoto T. I., Kashiwazaki H., Miyama T., Metabolic fate of ethylmercury salts in man and animal. Mercury, Mercurials, and Mercaptans ,Ch 12; 209-233. Miller M. W., Clarkson T. W., eds. Springfield: Charles C. Thomas, 1973. 6 Halsey N. A. Perspective on the use of thimerosal-containing vaccines. Presentation at the National Vaccine Advisory Committee Workshop on Thimerosal and Vaccines, August 11-12, 1999. Institute of Vaccine Safety website; www.vaccinesafety.edu. 7 Egan, W. M. Thimerosal in Vaccines. Presentation to the FDA, September 14, 1999.
8 Gosselin R. E., Smith R. P., Hodge H. C. Mercury. Clinical Toxicology of Commercial Products, Section III, Therapeutic Index,5th edn. Baltimore: Williams & Wilkins, 1984: 262-271.
9 Dales L. D. The neurotoxicity of alkyl mercury compounds. Am J Med 1972; 53: 219-232.
10 Koos B. J., Longo L. D., Mercury toxicity in the pregnant woman, fetus, and newborn infant. Am J Obstet Gynecol 1976: 126(3): 390-406.
11 Warkany J., Hubbard D. H. Acrodynia and mercury. J Pediatrics 1953: 42; 365-386.
12 McDougle C. J., Brodkin E. S., Yeung P. P., Naylor S. T., Cohen D. J., Price L. H. Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 1995; 5(4): 273-282.
13 Jaselskis C., Cook E., Fletcher K., Bennett L. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Pharmacol 1992.
14 Piven J., Palmer P. Psychiatric disorder and the broad autism phenotype: evidence from a family study of multiple-incidence autism families. Am J Psychiatry 1999; 156(4): 557-563.
15 Clarke D., Baxter M., Perry D., Prasher V. The diagnosis of affective and psychotic disorders in adults with autism: seven case reports. Autism 1999; 3(2): 149-164.
16 Muris P., Steerneman P., Merckelbach H., Holdrinet I., Meesters C. Comorbid anxiety symptoms in children with pervasive developmental disorders. J Anxiety Disord 1998; 12(4): 387-393.
17 Wing L., Attwood A. Syndromes of autism and atypical development. Handbook of Autism and Pervasive Developmental Disorders. John Wiley & Sons, Inc. 1987: 3-19.
18 Fagala G. E.,Wigg C. L. Psychiatric manifestations of mercury poisoning. J Am Acad Child Adolesc Psychiatry 1992; 31(2): 306-311.
19 Kark R. A., Poskanzer D .C., Bullock J. D., Boylen G. Mercury poisoning and its treatment with N-acetyl-D., L-penicillamine. N Engl J Med 1971; 285: 10-16.
20 White R. F., Feldman R. G., Moss M. B., Proctor S. P. Magnetic resonance imaging (MRI), neurobehavioral testing, and toxic encephalopathy: two cases. Environ Res 1993; 61: 117-123.
21 O’Carroll R. E., Masterton G., Dougnall N., Ebmeier K. P. The neuropsychiatric sequelae of mercury poisoning: The Mad Hatters disease revisited. Br J Psychiatry 1995; 167(1): 95-98.
22 Florentine M. J., Sanfilippo II D. J. Grand rounds: elemental mercury poisoning. Clin Pharm 1991; 10: 213-221.
23 Amin-Zaki, L., Elhassani S., Majeed M. A., Clarkson T. W., Doherty R. A., Greenwood M., Intra-uterine methylmercury poisoning in Iraq. Pediatrics 1974; 54(5) 587-595.
24 Amin-Zaki L., Majeed M. A., Elhassani S. B., Clarkson T. W., Greenwood M. R., Doherty R. A., Prenatal methylmercury poisoning. Am J Disabled Child 1979; 133: 172-177.
25 Joselow M. M., Louria D. B., Browder A. A., Mercurialism: environmental and occupational aspects. Ann Intern Med 1972; 76: 119-130.
26 Smith D. Mental Effects of Mercury Poisoning. Presentation before the Section on Family Practice, Southern Medical Association, 71st Annual Scientific Assembly, November 6-9, 1977.
27 Lowell J. A., Burgess S., Shenoy S., Curci J. A., Peters M., Howard T. K. Mercury poisoning associated with high-dose hepatitis-B immune globulin administration after liver transplantation for chronic hepatitis B. Liver Transpl Surg 1996; 2(6): 475-478.
28 Clarkson, T. The toxicology of mercury. Crit Rev Clin Lab Sci 1997; 34(3): 369-403.
29 Camerino D., Cassito M.G., Desideri E., Angotzi G. Behavior of some psychological parameters of a population of a Hg extraction plant. Clin Toxicol 1981; 18(11): 1299-1309.
30 Snyder R. D. The involuntary movements of chronic mercury poisoning. Arch Neurol 1972; 26: 379-381.
31 Vroom F. Q., Greer M. Mercury vapour intoxication. Brain 1972; 95: 305-318.
32 Adams C. R., Ziegler D. K., Lin J. T. Mercury intoxication simulating amyotrophic lateral sclerosis. JAMA 1983; 250: 642-643.
33 Cuomo V., Ambrosi L., Annau Z., Cagiano R., Brunello N., Racagni G. Behavioural and neurochemical changes in offspring of rats exposed to methylmercury during gestation. Neuobehav Toxicol Teratol 1984; 6(3): 249-254.
34 Tsubaki T., Irukayama K., eds. Minamata Disease. Elsevier Scientific Publishing Co., 1977.
35 Elsner J. Testing strategies in behavioral teratology. III. Microanalysis of behavior. Neurobehav Toxicol Teratol 1986; 8: 573-584.
36 Dawson G. Brief report: neuropsychology of autism: a report on the state of the science. J Autism Dev Disord 1996; 26(2): 179-184.
37 Pierce P. E., Thompson J. F. MPH, Likosky W. H. MD, Nickey L. N. MD, Barhtel W. F., Hinman A. R. MD MPH. Alkyl mercury poisoning in humans. JAMA 1972; 220(11): 1439-1442.
38 Grandjean P., Weihe P., White R. F., Debes F. Cognitive performance of children prenatally exposed to “safe” levels of methylmercury. Environ Res 1998; 77(2): 165-172.
39 Amin-Zaki L., Majeed M. A., Clarkson T. W., Greenwood M. R. Methylmercury poisoning in Iraqi children: clinical observations over two years. British Medical Journal 1978; March 1: 613-616.
40 Clarkson T. W. Mercury: major issues in environmental health. Environ Health Perspect 1992; 100: 31-38.
41 Kugler B. The differentiation between autism and Asperger syndrome. Autism 1998; 2(1): 11-32.
42 Teitelbaum P., Teitelbaum O., Nye J., Fryman J., Maurer R. G. Movement analysis in infancy may be useful for early diagnosis of autism. Proc Natl Acad Sci U S A 1998; 95: 13982-13987.
43 Tsai L. Y. Brief report: comorbid psychiatric disorders of autistic disorder. J Autism Dev Disord 1996; 26(2): 159-164.
44 Cesaroni L., Garber M. Exploring the experience of autism through firsthand accounts. J Autism Dev Disord 1991; 21(3): 303-313.
45 Farnsworth D. Pink Disease Survey Results. Pink Disease Support Group Site, 1997; www.users.bigpond.com/difarnsworth .
46 Brasic J. R. Movements in autistic disorder. Med Hypoth 1999; 53: 48-49.
47 Rosenhall U., Nordin V., Sandstrom M., Ahlsen G., Gillberg C. Autism and hearing loss. J Autism Dev Disord 1999; 29(5): 349-358.
48 Roux S., Adrien J-L., Bruneau N., Malvy J., Barthelemy C. Behavior profiles within a population of 145 children with autism using the Behaviour Summarized Evaluation scale: influence of developmental age. Autism 1998; 2(4): 345-366.
49 Baranek G. Autism during infancy: a retrospective video analysis of sensory-motor and social behaviors and 9-12 months of age. J Autism Dev Disord 1999; 29(3): 213-224.
50 ONeill M., Jones R. S. P. Sensory-perceptual abnormalities in autism: a case for more research? J Autism Dev Disord 1997; 27(3): 283-293.
51 Sperry V. W. Family and personal section: from the inside out – a view of the world as seen by one with Asperger syndrome. Autism 1998; 2(1): 81-86
52 Cass H. Visual impairment and autism: current questions and future research. Autism 1998; 2(2): 117-138.
53 Manser N. Neville’s (a Pinkie) Recollection of Pink Disease. Pink Disease Support Group; www.users.bigpond.com/difarnsworth.
54 Minshew N. J. Brief report: brain mechanisms in autism: functional and structural abnormalities. J Autism Dev Disord 1996; 26(2): 205-209.
55 Plioplys A. V., Hemmens S. E., Regan C. M. Expression of a neural cell adhesion molecule serum fragment is depressed in autism. J Neuropsychiatry Clin Neurosci 1990; 2(4): 413-417.
56 Sarafian T. A., Bredesen D. E., Verity M. A. Cellular resistance to methylmercury. Neurotoxicology 1996 Spring Abstract; 17(1): 27-36.
57 Hassett-Sipple B., Swartout J., Schoeny R. Vol. V. Health effects of mercury and mercury compounds. Mercury Study Report to Congress. Environmental Protection Agency (EPA), December 1997.
58 Pendergrass J. C., Haley B. E., Vimy M. J., Winfield S. A., Lorscheider F. L. Mercury vapor inhalation inhibits binding of GTP to tubulin in rat brain: similarity to a molecular lesion in Alzheimer diseased brain. Neurotoxicology 1997; 18(2): 315-324.
59 Dey P. M., Gochfeld M., Reuhl K. R. Developmental methylmercury administration alters cerebellar PSA-NCAM expression and Golgi sialyltransferase activity. Brain Res 1999; 845(2): 139-151.
60 Courchesne E., et al. More evidence links autism, cerebellar defects. reviewed in Autism Research Review International 1994; 8(2): 1,7.
61 Ritvo E. R., Freeman B. J., Scheibel A. B., et al. Lower Purkinje cell counts in the cerebella of four autistic subjects: intitial findings of the UCLA-NSAC Autopsy Research Report. Am J Psychiatry 1986; 143: 862-866.
62 Hoon A. H., Riess A. L. The mesial-temporal lobe and autism: case report and review. Dev Med Child Neurol 1992; 34: 252-265.
63 Piven J., Berthier M., Starkstein S., Nehme E., Pearlson G., Folstein S. Magnetic resonance imaging evidence for a defect of cerebral cortical development in autism. Am J Psychiatry 1990; 147(6): 734-739.
64 Abell F., Krams M., Ashburner J., et al. The neuroanatomy of autism: a voxel-based whole brain analysis of structural scans. Neuroreport 1999; 10(8): 1647-1651.
65 Aylward E. H., Minshew N. J., Goldstein G., et al. MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults. Neurology 1999; 53(9): 2145-2150.
66 Otsuka H. Brain metabolites in the hippocampus-amygdala region and cerebellum in autism: an 1H-MR spectroscopy study. Neuroradiology 1999; July.
67 Sears L. L. An MRI study of the basal ganglia in autism. Prog Neuropsychopharmacol Biol Psychiatry 1999; May.
68 Hashimoto T., Tayama M., Murakawa K., et al. Development of the brainstem and cerebellum in autistic patients. J Autism Dev Disord 1995; 25(1): 1-18.
69 McClelland R. J., Eyre D., Watson D., Calvert J. A neurophysiological study of autistic children. Electroencephalogr Clin Neurophysiol 1985; 61: 16.
70 Davis L. E., Kornfeld M., Mooney H. S., et al. Methylmercury poisoning: long term clinical, radiological, toxicological, and pathological studies of an affected family. Ann Neurol 1994: 35(6): 680-688.
71 Larkfors L., Oskarsson A., Sundberg J., Ebendal T. Methylmercury induced alterations in the nerve growth factor level in the developing brain. Brain Res Dev Brain Res 1991; 62(2): 287-291.
72 Lorscheider F. L., Vimy M. J., Summers A. O. Mercury exposure from “silver” tooth fillings: emerging evidence questions a traditional dental paradigm. FASEB J 1995; 9: 504-508.
73 Magos L., Brown A. W., Sparrow S., Bailey E., Snowden R. T., Skipp W. R. The comparative toxicology of ethyl- and methylmercury. Arch Toxicol 1985; 57(4): 260-267.
74 Rolls E. T. Memory systems in the brain. Ann Rev Psychol 2000; 51: 599-630.
75 Bachevalier J. Medial temporal lobe structures: a review of clinical and experimental findings. Neuropsychologia 1994; 32: 627-648.
76 Chugani D. C., Muzik O., Behen M., et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999; 45.
77 Cook E. H. Autism: review of neurochemical investigation. Synapse 1990; 6: 292-308.
78 OKusky J. R., Boyes B. E., McGeer E. G. Methylmercury-induced movement and postural disorders in developing rat: regional analysis of brain catecholamines and indoleamines. Brain Res 1988; 439(1-2): 138-146.
79 Nishio H., Nezasa K., Hirano J., Nakata Y. Effects of thimerosal, an organic sulfhydryl modifying agent, on serotonin transport activity into rabbit blood platelets. Neurochem Int 1996; 29(4): 391-396.
80 McKay S. J., Reynolds J. N., Racz W. J. Effects of mercury compounds on the spontaneous and potassium-evoked release of [3H]dopamine from mouse striatal slices. Can J Physiol Pharmacol 1986; 64(12): 1507-1514.
81 Hrdina P. D., Peters D. A., Singhal R. L. Effects of chronic exposure to cadmium, lead and mercury of brain biogenic amines in the rat. Research Communications in Chemistry, Pathology and Pharmacology 1976; 15(3): 483-493.
82 Moreno H., Borjas L., Arrieta A., et al. Clinical heterogeneity of the autistic syndrome: a study of 60 families (Spanish). Invest Clin 1992; 33(1): 13-31.
83 Perry E., Lee M., Court J., Perry R. Cholinergic Activities in Autism: Nicotinic and Muscarinic Receptor Abnormalities in the Cerebral Cortex. Presentation to Cure Autism Now, 2000.
84 Lewine magnetoenchalography in children with an autistic epileptiform regression. J Pediatrics 1999; 405-418.
85 Nass R., Gross A., Devinsky O. Autism and autistic epileptiform regression with occipital spikes. Dev Med Child Neurol 1998; 40(7): 453-8.
86 Brenner R. P, Snyder R. D. Late EEG finding and clinical status after organic mercury poisoning. Arch Neurol 1980; 37(5): 282-284.
87 Piikivi L., Tolonen U. EEG findings in chlor-alkali workers subject to low long term exposure to mercury vapor. Br J Ind Med 1989; 46(6): 370-375.
88 Rohyans J., Walson P. D., Wood G. A., MacDonald W. A. Mercury toxicity following merthiolate ear irrigations. J Pediatr 1984: 311-313.
89 Szasz A., Barna B., Szupera Z., et al. Chronic low-dose maternal exposure to methylmercury enhances epileptogenicity in developing rats. Int J Devl Neurosci 1999; 17(7): 733-742.
90 Scheyer R. D. Involvement of glutamate in human epileptic activities. Prog Brain Res 1998; 116, 359-369.
91 OReilly B. A., Waring, R. Enzyme and sulfur oxidation deficiencies in autistic children with known food/chemical intolerances. Journal of Orthomolecular Medicine 1993; 4: 198-200.
92 Alberti A., Pirrone P., Elia M., Waring R. H., Romano C. Sulphation deficit in “low-functioning” autistic children: a pilot study. Biol Psychiatry 1999; 46(3): 420-4.
93 Markovich D., Knight D., Renal Na-Si cotransporter NaSi-1 is inhibited by heavy metals. American Journal of Renal Physiology 1998; 274(2): 283-289.
94 Golse B., Debray-Ritzen P., Durosay P., Puget K., Michelson A. M. Alterations in two enzymes: superoxide dismutase and glutathion peroxidase in developmental infantile psychosis. Rev Neurol (Paris) 1978; 134(11): 699-705.
95 Edelson S. B., Cantor D. S. Autism: xenobiotic influences. Toxicol Ind Health 1998; 14(4): 553-563.
96 Fuchs J., Packer L., Zimmer G. Lipoic Acid in Health and Disease . Marcel Dekker, Inc., 1997
97 Williams M. V., Winters T., Waddell K. S. In vivo effects of Mercury (II) on deoxyuridine triphosphate nucleotidohydrolase, DNA polymerase (a,b), uracil-DNA glycosylase activities in cultured human cells: relationship to DNA damage, DNA repair, and cytotoxicity. Mol Pharmacol 1987; 31(2): 200-207.
98 Aukrust P., et al. Decreased levels of total and reduced glutathione in CD4+ lymphocytes in common variable immunodeficiency are associated with activation of the tumor necrosis factor system: possible immunopathogenic role of oxidative stress. Blood 1995;86(4): 1383-1391.
99 Jaffe J. S., et al. Functional abnormalities of CD8+ t cells define a unique subset of patients with common variable immunodeficiency. Blood 1993; 82(1): 192-201.
100 Shenker B. J., Guo T. L., Shapiro I. M. Low-level methylmercury exposure causes human T-cells to undergo apoptosis: evidence of mitochondrial dysfunction. Environ Res 1998; Section A 77(2): 149-159.
101 Page T., Yu A., Fontanesi J., Nyhan W. L. Developmental disorder associated with increased cellular nucleotidase activity. Proc Natl Acad Sci U S A 1997; 94: 11601-11606.
102 Page T., Coleman M. Purine metabolism abnormalities in a hyperuricosuric subclass of autism. Biochim Biophys Acta 2000; 1500(3): 291-296.
103 Plioplys A. Autism: Biomedical Perspectives. Presentation for the Autism Society of America meeting, July 1989.
104 Connolly A. M., et al. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr 1999; 134(5): 607-613.
105 Singh V., Warren R., Odell J., Warren W., Cole P. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun 1993; 7(1): 97-103.
106 Comi A. M., Zimmerman A., et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 1999; 14: 388-394.
107 Whiteley P., Rogers J., Shattock P. Clinical features associated with autism: observations of symptoms outside the diagnostic boundaries of autistic spectrum disorders. Autism 1998;2(4): 415-422.
108 Warren R. P., Margaretten N. C., Pace N. C., Foster A. Immune abnormalities in patients with autism. J Autism Dev Disord 1986; 16(2): 189-197.
109 Zimmerman A., Frye V. H., Potter N. T. Immunological aspects of autism. International Journal of Pediatrics 1993; 8: 199-204.
110 Weitzman A., Weisman R., Szekely G. A., Wijsenbeek H., Livni E. Abnormal immune response to brain tissue antigen in the syndrome of autism. Am J Psychiatry 1982; 139(11): 1462-1465.
111 Nielsen J. B., Hultman P. Experimental studies on genetically determined susceptibility to mercury-induced autoimmune response. Ren Fail 1999; 21(3&4): 343-348.
112 Hu H., Abedi-Valugerdi M., Moller G. Pretreatment of lymphocytes with mercury in vitro induces a response in T cells from genetically determined low-responders and a shift of the interleukin profile. Immunology 1997; 90: 198-204.
113 Al-Balaghi S., Möller E., Möller G., Abedi-Valugerdi M. Mercury induces polyclonal B cell activation, autoantibody production and renal immune complex deposits in young (NZB x NZW) F1 hybrids. Eur J Immunol 1996; 26(7): 1519-1526.
114 Warren R. P., Margaretten N. C., Foster A., Reduced natural killer cell activity in autism. J Am Acad Child Adolesc Psychiatry 1987; 26(3): 333-335.
115 Gupta S., Aggarwal S., Heads C., Brief report: dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics, J Autism Dev Disord 1996; 26(4): 439-452.
116 Messahel S., Pheasant A. E., Pall H., Ahmed-Choudhury J., Sungum-Paliwal R. S., Vostanis P. Urinary levels of neopterin and biopterin in autism. Neurosci Lett 1998; 241(1): 17-20.
117 Johansson U., Hansson-Georgiadis H., Hultman P. The genotype determines the B cell response in mercury-treated mice. Int Arch Allergy Immunol 1998; 116(4): 295-305.
118 Bagenstose L. M., Salgame P., Monestier M. Murine mercury-induced autoimmunity: a model of chemically related autoimmunity in humans. Immunol Res 1999; 20(1): 67-78.
119 Hu H., Moller G., Abedi-Valugerdi M. Mechanism of mercury-induced autoimmunity: both T helper 1- and T helper 2-type responses are involved. Immunology 1999; 96(3): 348-357.
120 Ilback N. G. Effects of methyl mercury exposure on spleen and blood natural-killer (NK) cell-activity in the mouse. Toxicology 1991; 67(1): 117-124.
121 Mattsson J. R., Miller E., Alligood J. P., Koering J. E., Levin S. G. Early effects of methylmercury on the visual evoked response of the dog. Neurotoxicology 1981; 2(3): 499-514.
122 Redwood, L. Chelation case histories. Http://tlredwood.home.mindspring.com/case_studies.htm.
124 Gilberg C., Wing L. Autism: not an extremely rare disorder. Acta Psychiatr Scand 1999; 99(6); 399-406.
123 Kanner L. Autistic disturbances of affective contact. The Nervous Child 1942-1943; 2(3): 217-250.
125 Bristol M., Cohen D., Costello E., et al. State of the science in autism: report to the National Institutes of Health. J Autism Dev Disord 1996; 26(2): 121-157.
126 Prevalence of Autism in Brick Township, New Jersey, 1998: Community Report. Centers for Disease Control and Prevention, April 2000; www.cdc.gov/nceh/cddh/dd/rpttoc.
127 Sager. P. R., Aschner, M., Rodier, P. M. Persistent differential alteration in developing cerebellar cortex of male and female mice after methylmercury exposure. Dev Brain Res 1984; 12: 1-11.
128 Rossi A. D., Ahlbom E., Ogren S. O., Nicotera P., Ceccatelli S. Prenatal exposure to methylmercury alters locomotor activity of male but not female rats. Exp Brain Res 1997; 117(3): 428-436.
129 Uproar over a little-known preservative, thimerosal, jostles U.S. hepatitis B vaccination policy. 1999 Summer; 4(2).
130 Capps L., Kehres J., Sigman M. Conversational abilities among children with autism and children with developmental delays. Autism 1998; 2(4): 325-44.
131 Tonge B. J., Brereton A. V., Gray K. M., Einfeld S. L., Behavioural and emotional disturbance in high-functioning autism and Aspergers syndrome. Autism 1999; 3(2): 117-130.
132 Ross W. Donald, Gechman A., Sholiton M., Paul H. Alertness to neuropsychiatric manifestations. Compr Psychiatry 1977; 18(6): 595-598.
133 Howlin P. Outcome in adult life for more able individuals with autism or Asperger syndrome. Autism 2000; 4(1): 63-84.
134 Klin A., Sparrow S. S., de Bilt A., et al. A normed study of face recognition in autism and related disorders. J Aut Dev Disorders 1999; 29(6): 499-508.
135 DeLong G. R. Autism: new data suggest a new hypothesis. Neurology 1999; 52(5): 911-916.
136 Bernabei P., Camaioni L., Levi G. An evaluation of early development in children with autism and pervasive developmental disorders from home movies: preliminary findings. Autism 1998; 2(3): 243-258.
137 Baron-Cohen S., Allen J., Gillberg C. Can autism be detected at 18 months: the needle, the haystack, and the CHAT. Br J Psychiatry 1992; 161: 839-843.
138 Eisenmayer R., et al. Delayed language onset as a predictor of clinical symptoms in pervasive developmental disorders. J Autism Dev Disord 1998; 28(6): 527-533.
139 Prizant B. M. Brief report: communication, language, social, and emotional development. J Autism Dev Disord 1996; 26(2): 173-178.
140 Grandin T. The learning style of people with autism: an autobiography. Teaching Children with Autism. Kathleen Ann Quill, ed., 1995: 33-52.
141 Hua M. S., Huang C. C., Yang Y. J. Chronic elemental mercury intoxication: neuropsychological follow up case study. Brain Inj 1996; 10(5): 377-384.
142 Yeates K. O., Mortensen M. E. Acute and chronic neuropsychological consequences of mercury vapor poisoning in two early adolescents. J Clin Exp Neuropsychol
143 Aronow R., Fleischmann L. Mercury poisoning in children. Clin Pediatr 1976; 15(10): 936-945.
144 Watzl B., Abrahamse SL., Treptow-van Lishaut S., et al. Enhancement of ovalbumin-induced antibody production and mucosal mast cell response by mercury. Food Chem Toxicol 1999; 37(6): 627-637.
145 Church C., Coplan J. The high functioning autistic experience: birth to preteen years. J Pediatr Health Care 1995; 9: 22-29.
146 ONeill J. L. Through the Eyes of Aliens. Jessica Kingsley Publishers Ltd., 1999.
147 Deufemia P., Celli M., Finocchiaro R., et al. Abnormal intestinal permeability in children with autism. Acta Pædiatr 1996; 85: 1076-1079.
148 Horvath K., Papadimitriou J. C., Rabsztyn A., Drachenberg C., Tildon J. T. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999; 135(5): 559-563.
149 Wakefield A. J., Murch S. H., Anthony A., et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637-641.
150 Shattock P., Savery D. Autism as a Metabolic Disorder. Sunderland, UK: Autism Research Unit, University of Sunderland, 1997.
151 Edelson M. G., Schubert D. T., Edelson S. M. Factors predicting intelligence cores on the TONI in individuals with autism. Focus on Autism and Other Developmental Disabilities 1998; 13(1): 17-26.
152 Long term follow-up: early intervention effects lasting. ARI Newsletter, review 1993; 7(1): 1&6
153 Rumsey J. Conceptual problem-solving in highly verbal, nonretarded autistic men. J Autism Dev Disord 1985; 15(1): 23-36.
154 Gedye A. Anatomy of self-injurious, stereotypic, and aggressive movements: evidence for involuntary explanation. J Clin Psychol 1992; 48(6): 766-778.
155 Kim J. A., Szatmari P., Bryson S. E., Streiner D. L., Wilson F. J. The prevalence of anxiety and mood problems among children with autism and Asperger syndrome. 2000; 4(2); 117-133.
156 Richdale A. L. Sleep problems in autism: prevalence, cause, and intervention. Dev Med Child Neurol 1999; 41(1): 60-66.
157 Stores G., Wiggs L. Abnormal sleeping patterns associated with autism: a brief review of research findings, assessment methods and treatment strategies. Autism 1998; 2(2): 157-170.
158 Sarafian T., Verity M..A. Altered patterns of protein phosphorylation and synthesis caused by methyl mercury in cerebellar granule cell culture. J Neurochem 1990; 55(3): 922-929.
159 Rosenspire A. J., Bodepudi S., Mathews M., McCabe M. J. Jr. Low levels of ionic mercury modulate protein tyrosine phosphorylation in lymphocytes. Int J Immunopharmacol 1998; 20(12): 697-707.
160 Rajanna B., Hobson M. Influence of mercury on uptake of [3H]dopamine and [3H]norepinephrine by rat braisynaptosomes. Toxicol Lett 1985; 27(1-3): 7-14.
161 Aschner M., Mullaney KJ., Wagoner D., Lash LH., Kimelberg HK. Intracellular glutathione (GSH) levels modulate mercuric chloride (MC)- and methylmercuric chloride (MeHgCl)-induced amino acid release from neonatal rat primary astrocytes cultures. Brain Res 1994; (664); 133-140.
162 Ashour H., Abdel-Rahman M., Khodair A. The mechanism of methyl mercury toxicity in isolated rat hepatocytes. Toxicol Lett 1993; 69(1): 87-96.
163 Atchison W. D., Hare M. F. Mechanisms of methylmercury-induced neurotoxicity, FASEB J 1994; 8(9): 622-629.
164 Faro L. R. F., Nascimento J. L. M., Alfonso M., Duran R., Acute administration of methylmercury changes in vivo dopamine release from rat striatum. Bull Environ Contam Toxicol 1998; 60: 632-638.
165 El-Fawal H. A., Waterman S. J., De Feo A., Shamy M. Y. Neuroimmunotoxicology: humoral assessment of neurotoxicity and autoimmune mechanisms. Environ Health Perspect 1999; 107(Suppl 5): 767-775.
166 Tan X. X., Tang C., Castoldi A. F., Manzo L., Costa L. G. Effects of inorganic and organic mercury on intracellular calcium levels in rat T lymphocytes. J Toxicol Environ Health 1993; 38(2): 159-170.
167 Elferink J. G. Thimerosal: a versatile sulfhydryl reagent,calcium mobilizer, and cell function-modulating agent. Gen Pharmacol 1999; 33(1): 1-6.
168 Atchison W. D., Joshi U., Thornburg J. E. Irreversible suppression of calcium entry into nerve terminals by methylmercury. J Pharmacol Exp Ther 1986; 238(2): 618-624.
169 Chu C. C., Huang C. C., Ryu S. J., Wu T. N. Chronic inorganic mercury induced peripheral neuropathy. Acta Neurol Scand 1998; 98(6): 461-465.
170 Coccini T., Randine G., Candura S. M., Nappi R. E., Prockop L. D., Manzo L. Low-level exposure to methylmercury modifies muscarinic cholinergic receptor binding characteristics in rat brain and lymphocytes: physiologic implications and new opportunities in biologic monitoring. Environ Health Perspect 2000; 108(1): 29-33.
171 Volterra A., Trotti D., Cassutti P., et al. High sensitivity of glutamate uptake to extracellular free arachidonic acid levels in rat cortical synaptosomes and astrocytes. J Neurochem 1992: 59(2): 600-606.
172 Lombard J. Autism: a mitochondrial disorder? Med Hypotheses 1998; 50(6): 497-500.
173 Gupta S., Aggarwal S., Rashanravan B., Lee T. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 1998; 85(1): 106-109.
174 Singh V. K. Plasma increase of Interleuken-12 and Interferon-gamma. Pathological significance in autism. J Neuroimmunology 1996; 66: 143-145.
175 Fombonne E., Rogé B., Claverie J., Courty S., Frémolle J. Microcephaly and macrocephaly in autism. J Autism Dev Disord 1999; 29(2): 113-119.
176 Carlsson M. L. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate – serotonin interactions for pharmacotherapy. J Neural Transm 1998; 105(4-5): 525-535.
177 Gillberg C., Svennerholm L. CSF monoamines in autistic syndromes and other pervasive dev. disorders of early childhood. Br J Psychiatry 1987; (151): 89-94.
178 Ernst M., Zametkin A. J., Matochik J. A., Pascualvaca D., Cohen R. M. Low medial prefrontal dopaminergic activity in autistic children. Lancet 1997; 350(9078): 638.
179 Leboyer M., Philippe A., Bouvard M., et al. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol Psycatry 1999; 45(2): 158-163.
180 Ornitz E. M. Neurophysiologic studies of infantile autism. Handbook of Autism and Pervasive Developmental Disorders. John Wiley & Sons, Inc., 1987: 148-165.
181 Schuler A. L. Thinking in autism: differences in learning and development. Teaching Children with Autism. Kathleen Ann Quill, ed., 1995: 11-32.Share